📊 INSM Key Takeaways
Is INSMED Inc (INSM) a Good Investment?
Insmed demonstrates strong revenue growth of 66.7% YoY, indicating product market traction, but is burning cash aggressively with -$226.2M free cash flow despite $306M in revenue, signaling fundamental profitability challenges. While the balance sheet is solid ($582.2M cash, 4.47x current ratio), the -50.1% operating margin and -$163.6M net loss create material downside risk unless the company can achieve near-term operational leverage.
Insmed is delivering strong top-line growth, with revenue up 66.7% year over year, but that growth is currently low quality because it is accompanied by deeply negative operating and free cash flow margins. The balance sheet and liquidity position provide some runway, yet the scale of losses, weak gross margin, and negative interest coverage indicate the business remains heavily dependent on continued external funding or major operating improvement.
Why Buy INSMED Inc Stock? INSM Key Strengths
- Strong top-line growth of 66.7% YoY demonstrates product demand and market acceptance
- Solid balance sheet with $582.2M in cash and 0.78x debt/equity provides financial runway of ~2.5 years at current burn rate
- Excellent liquidity position (4.47x current ratio, 4.10x quick ratio) ensures short-term operational stability
- Reasonable gross margin of 30.7% suggests viable product economics at manufacturing level
- Revenue growth is very strong at 66.7% year over year
- Liquidity is solid with a 3.83x current ratio and $510.44M in cash
- Debt/equity of 0.74x is manageable relative to many development-stage biotech peers
INSM Stock Risks: INSMED Inc Investment Risks
- Severe operating margin of -50.1% with -$153.3M operating loss indicates fundamental cost structure misalignment that revenue growth is not offsetting
- Negative free cash flow of -$226.2M annually is unsustainable; company is depleting cash reserves despite revenue growth, creating existential risk if burn rate persists
- Negative interest coverage ratio of -1.8x shows company cannot service debt from operations; entirely dependent on cash reserves
- Pharmaceutical sector inherently risky; path to profitability unclear, and revenue growth may decelerate while fixed costs remain high
- If revenue growth moderates while operating losses persist, cash runway shrinks rapidly, forcing dilutive financing or restructuring
- Operating margin of -205.6% shows the core business is far from self-sustaining
- Free cash flow of -$967.58M and operating cash flow of -$935.01M imply heavy cash burn
- Gross margin of 15.5% is weak for a pharmaceutical company and limits operating leverage
Key Metrics to Watch
- Operating margin trend - must move toward positive territory; even slight improvement to -30% would be concerning but directional signal
- Free cash flow trajectory - critical to see cash burn decline toward breakeven; current -$226.2M rate is unsustainable
- Cash balance depletion rate - monitor quarterly cash position relative to burn; risk of adequacy within 18-24 months if trends persist
- Gross margin sustainability - confirm 30.7% margin holds as revenue scales; margin compression would indicate pricing pressure or manufacturing inefficiency
- Operating cash burn and free cash flow trend
- Gross margin and operating margin improvement
INSMED Inc (INSM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.47x current ratio provides a solid financial cushion.
INSM Profit Margin, ROE & Profitability Analysis
INSM vs Healthcare Sector: How INSMED Inc Compares
How INSMED Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is INSMED Inc Stock Overvalued? INSM Valuation Analysis 2026
Based on fundamental analysis, INSMED Inc shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
INSMED Inc Balance Sheet: INSM Debt, Cash & Liquidity
INSM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: INSMED Inc's revenue has grown significantly by 222% over the 5-year period, indicating strong business expansion. The most recent EPS of $-5.34 indicates the company is currently unprofitable.
INSM Revenue Growth, EPS Growth & YoY Performance
INSM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $92.8M | -$163.6M | $-0.76 |
| Q3 2025 | $93.4M | -$220.5M | $-1.27 |
| Q2 2025 | $90.3M | -$300.6M | $-1.70 |
| Q1 2025 | $75.5M | -$157.1M | $-1.06 |
| Q3 2024 | $79.1M | -$158.9M | $-1.11 |
| Q2 2024 | $77.2M | -$244.8M | $-1.78 |
| Q1 2024 | $65.2M | -$157.1M | $-1.06 |
| Q3 2023 | $67.7M | -$131.1M | $-1.09 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
INSMED Inc Dividends, Buybacks & Capital Allocation
INSM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for INSMED Inc (CIK: 0001104506)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INSM
What is the AI rating for INSM?
INSMED Inc (INSM) has a Combined AI Rating of SELL from Claude (HOLD) and ChatGPT (SELL) with 64% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INSM's key strengths?
Claude: Strong top-line growth of 66.7% YoY demonstrates product demand and market acceptance. Solid balance sheet with $582.2M in cash and 0.78x debt/equity provides financial runway of ~2.5 years at current burn rate. ChatGPT: Revenue growth is very strong at 66.7% year over year. Liquidity is solid with a 3.83x current ratio and $510.44M in cash.
What are the risks of investing in INSM?
Claude: Severe operating margin of -50.1% with -$153.3M operating loss indicates fundamental cost structure misalignment that revenue growth is not offsetting. Negative free cash flow of -$226.2M annually is unsustainable; company is depleting cash reserves despite revenue growth, creating existential risk if burn rate persists. ChatGPT: Operating margin of -205.6% shows the core business is far from self-sustaining. Free cash flow of -$967.58M and operating cash flow of -$935.01M imply heavy cash burn.
What is INSM's revenue and growth?
INSMED Inc reported revenue of $306.0M.
Does INSM pay dividends?
INSMED Inc does not currently pay dividends.
Where can I find INSM SEC filings?
Official SEC filings for INSMED Inc (CIK: 0001104506) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INSM's EPS?
INSMED Inc has a diluted EPS of $-0.76.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INSM a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, INSMED Inc has a SELL rating with 64% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INSM stock overvalued or undervalued?
Valuation metrics for INSM: ROE of -23.2% (sector avg: 15%), net margin of -53.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INSM stock in 2026?
Our dual AI analysis gives INSMED Inc a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INSM's free cash flow?
INSMED Inc's operating cash flow is $-222.7M, with capital expenditures of $3.5M. FCF margin is -73.9%.
How does INSM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -53.5% (avg: 12%), ROE -23.2% (avg: 15%), current ratio 4.47 (avg: 2).